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tumors. After adjusting for age and tumor size, there were 
differences between the different treatments in terms of the 
PR rate, but no differences were observed in overall (OS) or 
disease-free survival. The hazard ratio for PR comparing SLR 
versus RT adjusted for age and tumor size was 2.73 (95% con-
fidence interval, CI, 0.72–10.27) and that for SLR versus RFA 
was 7.57 (95% CI 1.94–29.47).  Conclusions: Our study sug-
gests that SLR was associated with a higher primary tumor 
control rate compared to RFA or RT, although the OSs were 
not different. These results should be confirmed in prospec-
tive trials.  © 2015 S. Karger AG, Basel 
 Introduction 
 According to current guidelines, radical lobectomy re-
mains the standard of care for patients with clinical stage 
I non-small cell lung cancer (NSCLC). However, up to 
25% of patients with clinical stage I NSCLC cannot toler-
ate lobectomy secondary to their comorbid conditions 
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 Abstract 
 Background: The best therapy for patients with stage I non-
small cell lung cancer (NSCLC) who are medically unfit for 
lobectomy or prefer not to undergo surgery has not yet been 
demonstrated.  Objectives: We analyzed data from our pro-
spective database to evaluate the recurrence and survival 
rates and assess the extent to which the type of treatment 
explains outcome differences.  Methods: This study included 
116 patients with histologically proven clinical stage I NSCLC 
who were treated with sublobar resection (SLR; n = 42), ra-
diofrequency ablation (RFA; n = 25) or radiotherapy (RT; n = 
49) between 2009 and 2013. The primary end point was the 
time to primary tumor recurrence (PR). Kaplan-Meier curves 
and Cox regression were used to compare the recurrence 
patterns and survivals after adjustments for potential con-
founders.  Results: The SLR patients were younger and exhib-
ited better performance status. The RT patients had larger 
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 [1] . Less invasive modalities are being considered for 
these patients. Sublobar resection (SLR), also referred to 
as limited resection, is reserved for patients who are un-
able to tolerate lobectomy specifically to preserve pulmo-
nary function  [2] . SLR can be performed by nonanatom-
ical wedge resection or anatomical segmentectomy, 
which has been shown to be superior to wedge resection 
in terms of primary tumor control. Thoracic radiothera-
py (RT) and radiofrequency ablation (RFA) are reason-
able nonsurgical options for high-risk stage I NSCLC pa-
tients. RT can be performed as conventionally fraction-
ated radiotherapy (CFRT) or as stereotactic ablative body 
radiation (SABR), which was formerly referred to as ste-
reotactic body radiation therapy. SABR enables highly fo-
cal treatment of cancer with single or few fractions of 
high-dose radiation and is preferred to CFRT  [3] . RFA is 
a minimally invasive method that involves image-guided 
percutaneous placement of an electrode into a tumor and 
generation of heat to cause complete tumor destruction.
 For those who are not candidates for lobectomy, SLR 
is recommended over nonsurgical therapy. Because un-
treated patients with clinical stage I NSCLC have a poor 
median survival of only 14–18 months, nonsurgical abla-
tive treatment is preferred over no therapy for those who 
cannot tolerate SLR  [1] . However, the superiority of SLR 
over nonsurgical ablative treatment is controversial. Cur-
rently, results from randomized controlled trials compar-
ing surgery with nonsurgical ablative treatment are not 
available.
 In this study, we analyzed the survival, recurrence pat-
terns and treatment-related morbidity of high-risk oper-
able patients with potentially curable clinical stage I 
NSCLC after SLR, RT and RFA.
 Materials and Methods 
 Our institutional database query for patients with histological-
ly proven clinical stage I NSCLC (American Joint Committee on 
Cancer, 7th edition) who were treated with SLR, RFA or RT at 
Heidelberg University Hospital between January 2009 and Decem-
ber 2013 identified 174 cases. Patients with metachronous or pre-
sumed synchronous double lung tumors, nonbiopsied tumors or 
missing follow-up data were excluded. A total of 116 patients re-
mained eligible and were analyzed with institutional review board 
approval (study No.: 080/2006).
 Patients were staged with bone scans, computed tomography 
(CT) scans of the chest and upper abdomen and CT scans or mag-
netic resonance imaging of the brain. Mediastinoscopy or bron-
choscopy with endobronchial ultrasound was performed at the dis-
cretion of the tumor board if the CT or positron emission tomog-
raphy results were suggestive of mediastinal or hilar lymph node 
metastases. These cases were excluded if histological or cytological 
mediastinal assessment was lacking. Uncertain proof of malignan-
cy in the intraoperative frozen section prevented lobectomy in 7 
cases. These patients refused completion lobectomy within a sec-
ond operation. Ninety-four percent of the RT patients and 92% of 
the RFA patients were deemed medically inoperable for lobectomy. 
Six percent of the RT patients and 8% of the RFA patients refused 
surgery. Histology was attained in all cases ( table 1 ).
 Treatment 
 The type of treatment indicated was based on the consensus of a 
multidisciplinary team discussion. An SLR was termed an anatomi-
cal segmentectomy only if individual dissection and ligation of the 
segmental vessels and bronchus to an anatomically defined lung seg-
ment were performed; otherwise, we used the term atypical or wedge 
resection. When identifying a nodule or stapling lung parenchyma 
seemed difficult due to target location or characteristics, a limited 
anterolateral thoracotomy was necessary. We performed lymph 
node dissection or lymph node sampling only on an individual basis 
due to concerns about longer operative time and greater total chest 
tube drainage. Depending on tumor depth and location, 15 patients 
(36%) underwent video-assisted thoracoscopic surgery (VATS), and 
27 patients (64%) underwent limited anterolateral thoracotomy. Six 
patients (14%) underwent anatomical segmentectomy, and 36 pa-
tients (86%) underwent wedge resections. Twelve SLR patients 
(29%) underwent lymph node dissection and 4 SLR patients (9.5%) 
lymph node sampling. All RT patients underwent a 4-dimensional 
planning CT scan  [4] . Twenty-eight patients (57%) underwent 
SABR with a median total dose of 45 Gy, a median of 3 fractions and 
a median dose of 18 Gy/fraction. Twenty-one patients (43%) under-
went CFRT with a median total dose of 66 Gy, a median of 31 frac-
tions and a median dose of 2 Gy/fraction. We performed bipolar 
RFA under general anesthesia as previously described  [5] .
 Follow-Up 
 According to national guidelines, the follow-ups for all patients 
consisted of chest CT scans every 3 months for the first year, every 
6 months in the second year, and on an individual basis thereafter. 
Restaging was performed for clinically symptomatic patients. Ra-
diological evidence of recurrence was confirmed by biopsy. Pri-
mary tumor recurrence (PR) was defined as tumor recurrence in 
the former resection line or at the ablation site. The diagnosis of 
PR was based on biopsy (histology or cytology). Cases without de-
finitive diagnoses were excluded from the PR analysis. Locore-
gional recurrence was defined as PR or tumor recurrence in the 
same lobe, ipsilateral hilar or ipsilateral mediastinal lymph nodes. 
Any other tumor recurrence was defined as a distant recurrence. 
The primary end point was freedom from PR.
 Statistical Analyses 
 To compare the patient demographics and tumor characteris-
tics between the groups, 1-way analysis of variance (ANOVA) and 
χ 2 tests were used. For only the results that exhibited statistically 
significant differences, we performed independent sample t tests, 
and we report the p values from the pairwise comparisons. The 
time to recurrence was calculated from the time of the interven-
tion. To account for the competing risks while analyzing the pro-
gression-free survival, we performed a time-to-first event analysis 
in which death or any type of tumor recurrence was counted as an 
event  [6] . The differences in overall survival (OS), progression-free 
survival and time to recurrence were compared using pairwise log 
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rank tests with Kaplan-Meier plots for illustration. Due to the high 
number of comparisons, the resulting p values could not be ad-
justed for multiple comparisons and are therefore of a purely de-
scriptive nature. All variables were assessed for potential con-
founding effects in univariate and multivariable Cox regression 
models. Changes in the regression coefficients of more than 5% 
were regarded as indicative of confounding variables. The results 
of the Cox model are described as the means of the hazard ratios 
(HRs) together with the 95% confidence intervals (CIs), and the p 
values were based on the Wald test  [7] . The analyses were per-
formed with SPSS Statistics version 22 (IBM, Armonk, N.Y., USA) 
and were 2-sided.
 Results 
 Patient Characteristics 
 The SLR patients were significantly younger (SLR vs. 
RT: p = 0.012; SLR vs. RFA: p = 0.37) and exhibited better 
ECOG performance statuses (SLR vs. RT: p = 0.07; SLR 
vs. RFA: p = 0.024; RT vs. RFA: p = 0.10). The RT patients 
had larger tumors (SLR vs. RT: p = 0.001; SLR vs. RFA: 
p = 0.13; RT vs. RFA: p = 0.05) and were in advanced 
clinical stages (SLR vs. RT: p = 0.26; SLR vs. RFA: p = 0.12; 
 Table 1.  Patient demographics and tumor characteristics
SLR (n = 42) RT (n = 49) RFA (n = 25) p
Age, years 69.6 ± 7.1 73.5 ± 7.2 71.2 ± 6.4 0.01a
Range 53 – 84 57 – 89 55 – 80
Male 27 (64%) 34 (69%) 18 (72%) 0.78b
FEV1, % 69.4 ± 23.7 62.5 ± 27.0 67.1 ± 29.5 0.50a
Range 25 – 118 23 – 142 23 – 132
DLCO, % 58.4 ± 16.4 48.3 ± 19.6 50.3 ± 19.4 0.21a
Range 29 – 79 22 – 91 26 – 90
Charlson Comorbidity Index (age-adjusted) 5.9 ± 2.3 6.6 ± 2.4 6.2 ± 2.2 0.55a
Range 2 – 13 3 – 11 2 – 11
ECOG performance status <0.01b
0 18 (43%) 10 (20%) 4 (16%)
1 24 (57%) 32 (66%) 21 (84%)
2 0 7 (14%) 0
3 0 0 0
Prior cancer 12 (29%) 12 (24%) 7 (28%) 0.92b
Tumor size, mm 18.5 ± 9.5 28.4 ± 9.8 21.9 ± 7.3 <0.01a
Range 2 – 45 10 – 50 10 – 35
Clinical stagec 0.05b
T1N0M0 28 (67%) 27 (55%) 21 (84%)
T2N0M0 14 (33%) 22 (45%) 4 (16%)
Histology 0.25b
Adenocarcinoma 30 (71%) 27 (55%) 17 (68%)
Squamous cell carcinoma 11 (26%) 19 (39%) 6 (24%)
NSCLC not otherwise specified 0 3 (6%) 1 (4%)
Other NSCLC histology 1 (2%) 0 1 (4%)
Histology not attained 0 0 0
Criteria for ineligibility for anatomical lobectomy
Mental disease or status after stroke 3 (7%) 6 (12%) 2 (8%)
Alcohol abuse or liver cirrhosis 2 (5%) 3 (6%) 0
Age >84 years 1 (2%) 6 (12%) 0
Severe renal insufficiency 5 (12%) 5 (10%) 0
Pulmonary insufficiency 18 (43%) 30 (61%) 19 (76%)
Cardiac insufficiency 7 (17%) 19 (39%) 10 (40%)
Previous RT to lung 0 0 2 (8%)
Previous lung surgery 0 0 5 (2%)
Potentially operable – 3 (6%) 2 (8%)
 The data are presented as the absolute and relative frequencies in parentheses or means ± standard deviations.
a χ2 test.  b ANOVA test.  c Pathological stage in case of SLR.
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RT vs. RFA: p = 0.01). No significant differences were ob-
served between the groups in terms of the pulmonary 
function parameters, gender, comorbidity index, prior 
history of cancer or lung cancer histology ( table 1 ).
 Univariate Cox Regression 
 The median follow-ups for the SLR, RT and RFA pa-
tients were 18, 10 and 13 months, respectively. The prob-
abilities of 1- and 2-year OS were 94 and 85% for the SLR 
patients, 86 and 74% for RFA patients and 93 and 69% for 
the RT patients, respectively.  Table  2 summarizes the 
mean times to primary tumor and to locoregional, distant 
and any recurrence. The lungs were the most frequent 
initial site of distant recurrence in all three groups. An 
unadjusted comparison of recurrence using an univariate 
Cox model revealed better primary tumor control after 
SLR than after RT or RFA (SLR vs. RT: p = 0.03; SLR vs. 
RFA: p = 0.02; RT vs. RFA: p = 0.36). No statistically sig-
nificant differences were identified in distant metastasis 
(SLR vs. RT: p = 0.93; SLR vs. RFA: p = 0.84; RT vs. RFA: 
p = 0.48), freedom from any failure ( fig. 1 c) or OS ( fig. 1 d). 
The Kaplan-Meier curves for primary tumor control, lo-
coregional control, progression-free survival and OS are 
shown in  figure 1 .
 Effects of the Surgical Procedures and the 
Radiotherapy Types 
 To determine whether the type of surgical procedure 
affected the PR or OS, the surgical cases were divided into 
the following pairs of groups: (a) lymph node dissection 
(LND; n = 12) versus no LND (n = 30), (b) anatomical 
segmentectomy (n = 6) versus wedge resection (n = 36) 
and (c) open thoracotomy (n = 27) versus VATS (n = 15). 
No statistically significant differences were found in PR 
(LND vs. no LND: p = 0.64; segmentectomy vs. wedge:
p = 0.47; open vs. VATS: p = 0.82) or OS (LND vs. no 
LND: p = 0.84; segmentectomy vs. wedge: p = 0.75; open 
vs. VATS: p = 0.70). To investigate the effect of RT type 
on the PR and OS, we separated the RT group into SABR
(n = 27) and CFRT (n = 20) groups. No statistically sig-
nificant differences in PR (p = 0.92) or OS (p = 0.56) were 
identified between the SABR and conventionally ablated 
cases ( fig. 2 ).
 Multivariable Cox Regression 
 Pairwise comparisons between the three groups re-
vealed significant differences in age, tumor size, ECOG 
performance status and clinical stage. Thus, we utilized 
multivariable Cox regression models to evaluate the dif-
ferences in recurrence and survival while controlling for 
these potential confounders. Because the total number of 
events was limited in this data set, all possible confound-
ers were not analyzed in a single multivariable model to 
avoid overfitting. Therefore, we calculated several multi-
variable models that each included only a subset of the 
potential confounders and compared the results. ECOG 
performance status and clinical stage exhibited no influ-
ence on the HRs. The results of the final Cox regression 
model that adjusted for the variables of age and tumor 
size are summarized in  table 3 . The RFA patients exhib-
ited significantly increased risks for PR and locoregional 
tumor recurrence compared to the surgical patients. The 
HRs of 2.73 (95% CI = 0.72–10.27; p = 0.137) for RT and 
7.57 (95% CI = 1.94–29.47; p = 0.004) for RFA indicate 
that the risk of PR after nonsurgical treatment was great-
er than that after SLR ( table 3 ).
 Procedural Complications 
 One SLR patient was readmitted for ipsilateral pleural 
effusion. One SLR patient was reoperated on for postop-
SLR (n = 42) RT (n = 49) RFA (n = 25)
Mean time to primary tumor recurrence 20.0 (18.7) 6.8 (3.3) 8.8 (7.5)
Range 2 – 47 1 – 46 1 – 27
Mean time to locoregional recurrence 13.9 (6.7) 8.7 (7.0) 10.1 (8.1)
Range 2 – 47 1 – 46 1 – 47
Mean time to distant recurrence 10.3 (8.5) 6.7 (6.7) 11.4 (7.3)
Range 2 – 23 1 – 22 3 – 21
Mean time to any recurrence 11.8 (8.0) 6.0 (3.0) 11.9 (8.1)
Range 2 – 46 1 – 46 1 – 24
The data are presented as the absolute frequencies for ranges and means and standard 
deviations in parentheses.
 Table 2. Times (months) to tumor 
recurrence after SLR, RT and RFA
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erative hemothorax. Three SLR patients developed new-
onset postoperative atrial fibrillation. One SABR patient 
was readmitted for acute exacerbation of pain. One CFRT 
patient was readmitted 15 months after completing CFRT 
with grade 3 pneumonitis. One SABR patient developed 
grade 1 pneumonitis 2 months after the ablation. One 
CFRT patient was readmitted for grade 3 pneumonitis 3 
months after the ablation. One RFA patient was operated 
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 Fig. 1. Outcomes following SLR (n = 42), RT (n = 49) and RFA (n = 25) for stage I NSCLC. SLR, RT and RFA in 
terms of freedom from primary tumor failure ( a ), freedom from locoregional failure ( b ), progression-free sur-
vival ( c ) and OS ( d ). 
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on day 1 after RFA for a hemothorax. Three patients were 
readmitted after RFA for a contralateral pleural effusion, 
an ipsilateral pneumothorax on day 20 and a late-occur-
ring ipsilateral pneumothorax on day 41. Three RFA pa-
tients required pleurocentesis for pleural effusion early 
after RFA. In 7 RFA patients, chest tube insertions were 
performed for iatrogenic pneumothorax during or soon 
after RFA. No postoperative or postinterventional in-
hospital deaths occurred.
 Discussion 
 The purpose of this study was to compare the outcomes 
following alternative treatment options for 116 stage I 
NSCLC patients who were medically unfit for lobectomy 
or preferred not to undergo surgery. The alternative treat-
ment modalities seemed to be associated with reduced 
procedural morbidity and mortality, although the in-
creased risk for PR compared to anatomical lobectomy 
was a concern. We observed no mortalities and acceptable 
procedural morbidities following SLR, RT and RFA.
 The identification of so-called ‘high-risk’ patients re-
mains a clinical decision. A multidisciplinary team indi-
cated the procedure that best met each patient’s situa-
tion. Pulmonary function was the primary indication for 
alternative tumor therapy. The majority of patients could 
have been operated on according to the FEV 1 and D LCO 
values; however, combinations with other comorbidities 
were the primary reasons for foregoing standard lobec-
tomies.
 Unadjusted primary tumor recurrence analysis re-
vealed a significantly lower risk after SLR than after RFA 
or RT ( table 2 ;  fig. 1 ). However, the patients who under-
went SLR were younger and had better ECOG perfor-
mance statuses than did the RT and RFA patients ( ta-
ble 1 ). We found larger tumors in the RT patients, which 
might be attributable to the limitation of bipolar RFA to 
tumors >3 cm in diameter and the consequent exclusion 
of patients from surgery when centrally located malig-
nancies technically required lobectomy.
 To address the differences, we performed multivari-
able Cox regression. Only age and tumor size influenced 
the HRs. Multivariable analyses with adjustments for age 
and tumor size resulted in HRs that were indicative of a 
greater risk of PR in the nonsurgical groups. The HR for 
PR after RT was not statistically significant, which is pri-
marily attributable to the small sample size. Our results 
are in line with some retrospective analyses and data from 
nonrandomized prospective studies that suggest higher 
primary tumor control rates after RT and surgery com-
pared with RFA. The level of evidence regarding RFA and 
primary tumor control is low. The reported 2- and 3-year 
PR rates after RFA range from 12 to 43% and 8 to 37%, 
respectively.
 In our series, we observed lower PR rates after SLR 
than after SABR (9.5 vs. 20%). Retrospective and pro-
spective studies that have evaluated SABR for clinical 
stage I NSCLCs have reported 2- and 3-year primary tu-
mor control rates ranging from 78 to 98%  [8] . Results 
from RT studies need to be interpreted with caution be-
cause patients who are not candidates for resection are 
staged clinically. Primary tumor histologies are attained 
in all surgical cases, whereas the diagnoses rely on posi-
tron emission tomography/CT morphological criteria in 
a significant number of RT patients. The sensitivity of 
positron emission tomography/CT ranges between 68 
and 100%, but it only has a moderate positive predictive 
value  [9] .
 In a retrospective study that investigated tumor recur-
rence after SABR in 676 early stage NSCLC patients, the 
2-year rate of PR was 4.9%  [10] . Malignancy was proven 
in only 235 cases (35%). The majority of this population 
(n = 441; 65%) underwent SABR without previous proof 
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 Fig. 2. Primary tumor control after lung SLR (n = 42) versus RT
(n = 49) in general ablative body radiation and SABR (n = 27), and 
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of malignancy. In other studies in which histology was 
confirmed by biopsy in up to 100% of the cases before 
SABR was conducted for clinical stage I NSCLC, the 
2-year rates of PR have been reported to range from 7 to 
21%  [8] .
 We observed no difference in primary tumor control 
between CFRT and SABR. In contrast to our data, non-
randomized evidence suggests superior disease-specific 
survival and OS in stage I NSCLC following SABR com-
pared to CFRT. The same can be stated regarding wedge 
and anatomical segmentectomy cases because there is ev-
idence in the literature that, in contrast to our data, these 
types of surgery result in different disease-free survivals. 
The difference observed in our results might have result-
ed from the low sample size, which is a limitation of this 
study. Although some prospective clinical trials have re-
ported acceptable primary tumor control rates with SLR, 
RT and RFA, no direct comparative data from random-
ized controlled trials are available for this subset of oper-
able patients. These patients have been referred to as ‘bor-
derline surgical candidates’, ‘high-risk operable’ or ‘med-
ically inoperable’ patients. The imprecise definition has 
resulted in numerous biases that confound interpreta-
tion. Therefore, the numbers of comparisons reported 
here with respect to RT and RFA, which are worse than 
those reported elsewhere in the literature  [11] , necessitate 
caution in the interpretation of these results. In addition 
there was an inherent selection bias related to the general 
and primary tumor operabilities being defined by sur-
gery, which resulted in a decision algorithm that permit-
ted RT or RFA primarily only after surgery had been ex-
cluded. This bias not only allows, but also requires that it 
should be borne in mind that some primary tumor ther-
apy should occur even in cases in which the general pa-
tient status or tumor localization is unfavorable. In con-
trast, it is therefore conceivable that, based on the local-
ization in the lung, a number of suitable tumors that 
would have been better accessed and treated with RT or 
RFA went into the surgery arm. This patient selection bias 
was well reflected.
 Prospective trials that randomize medically inoperable 
patients to either surgery or ablative therapy are needed. 
Unfortunately, poor patient recruitment led to the pre-
mature closure of a randomized trial (NCT00687986) 
that intended to randomize patients with stage IA NSCLC 
to either surgery or SABR. Another randomized trial 
(NCT00840749) of lobectomy or pneumonectomy versus 
SABR also closed secondary to low accrual. The ACOSOG/
RTOG trial Z4099/1021 (NCT01336894) is comparing 
high-risk patients with stage I NSCLC treated with either 
SLR with or without brachytherapy to those treated with 
SABR. The estimated completion date is August 2019. In-
 Table 3. Uni- and multivariable Cox models adjusted for age and tumor size
Variable Unadjusted
HR
95% CI p HR adjusted
for age and
tumor size
95% CI p
Overall survival
SLR versus RT
SLR versus RFA
2.52
2.05
0.89 – 7.11
0.63 – 6.65
0.081
0.234
2.46
2.72
0.80 – 7.59
0.77 – 9.59
0.116
0.121
Progression-free survival
SLR versus RT
SLR versus RFA
1.66
1.85
0.81 – 0.85
0.85 – 4.03
0.170
0.123
1.39
1.79
0.64 – 2.97
0.82 – 3.92
0.403
0.143
Primary tumor recurrence
SLR versus RT
SLR versus RFA
3.89
5.94
1.07 – 14.18
1.57 – 22.43
0.040
0.009
2.73
7.57
0.72 – 10.27
1.94 – 29.47
0.137
0.004
Locoregional recurrence
SLR versus RT
SLR versus RFA
2.23
3.26
0.87 – 5.75
1.19 – 8.94
0.096
0.022
1.70
3.62
0.64 – 4.54
1.29 – 10.2
0.292
0.015
Regional recurrence
SLR versus RT
SLR versus RFA
2.05
1.67
0.56 – 7.50
0.37 – 7.67
0.278
0.507
1.65
1.73
0.41 – 6.60
0.37 – 8.11
0.480
0.489
Distant recurrence
SLR versus RT
SLR versus RFA
1.71
1.17
0.63 – 4.64
0.33 – 3.82
0.294
0.861
1.29
1.11
0.46 – 3.66
0.32 – 3.80
0.629
0.875
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deed, if completed, the results of this trial will not be avail-
able for some time. Therefore, we believe that retrospec-
tive studies such as ours, despite their limitations, might 
be helpful in guiding decisions for the individual treat-
ment of high-risk patients.
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